AVEO garners $100M from stock offering; Report: iPierian shakeup continues; Qiagen buying Ipsogen;

@FierceBiotech: Cancer immunotherapies in vogue as specialists seek a "cure." Story | Follow @FierceBiotech

@JohnCFierce: NIH is handing out $200M to five institutions for translational med work. Item | Follow @JohnCFierce

> AVEO Pharmaceuticals says it will net slightly more than $100 million on its sale of 5.75 million discounted shares, much of which will be used for its ambitious R&D plans. The developer recently grabbed an impressive $125 million upfront from its partnership with Astellas on tivozanib, a promising experimental cancer drug. Story

Xconomy reports that the shakeup at iPierian is continuing with the departure of Corey Goodman, its high-profile chairman, and Harvard stem cell expert Doug Melton, a member of the advisory committee. Story

> Stemgent has reportedly now taken in $10.6 million of a $14.1 million Series B. Report

> Qiagen said today that it will acquire France's Ipsogen, a diagnostics company which it values at €70 million. Story

> Meda says it presented positive Phase III data on Dymista, a treatment for allergic rhinitis. Release

Pharma News

@FiercePharma: Laid-off Pfizer reps join OT lawsuit. News | Follow @FiercePharma

> Study: Pfizer, BI inhaler boosts death risk. Report

> Sanofi moves deeper into Genzyme operations. News

> Roche's Herceptin sensitivity test wins FDA nod. Story

> FDA warns Dr Reddy's on Mexico plant's shortfalls. Item

> NC lawsuit shield falters in legislature. Article

Drug Delivery News

> Pfizer, pSivida deal is about big market in patient compliance. Piece

> New delivery system gives Parkinson's patients better quality of life. Article

> Mist inhaler to treat lung disease may not be safe. Report

> UK company looks to move from nutraceuticals to pharmaceuticals. Story

> Nanoparticle delivery into inner ear may help hearing loss. Article

> Singapore scientists design hydrogels that react to pH, temperature. Item

Medical Device News

> Covidien to shake up management structure. News

> Cordis to rein in stent development, cut jobs. Item

> QIAGEN looks to buy Ipsogen. Report

> CerebralRx's FitNes system launched in Europe. Article

> Secant to work with Solvant on biomedical implants. Story

> Spinal Modulation snags $30M in Series D. Report

And Finally... Biotech entrepreneur John Crowley--whose fight to develop a new treatment for Pompe disease to help two of his children became the basis for the movie "Extraordinary Measures"--may run for a Senate seat in New Jersey. Story

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.